Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 1/20 | 0.54 |
| ▸ | CDK2 | P24941 | 3/20 | 0.53 |
| ▸ | KIFC1 | Q9BW19 | 2/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.48 |
| ▸ | TACR3 | P29371 | 1/20 | 0.47 |
| ▸ | MDM4 | O15151 | 1/20 | 0.45 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.45 |
| ▸ | NOS3 | P29474 | 1/20 | 0.45 |
| ▸ | NOS1 | P29475 | 1/20 | 0.45 |
| ▸ | NOS2 | P35228 | 1/20 | 0.45 |
| ▸ | ELANE | P08246 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | GPR34 | Q9UPC5 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6400300 | 0.94 | KDR (0.56) | KDRCDK2KIFC1HDAC1HDAC6 | |
| SCHEMBL6400298 | 0.94 | KDR (0.56) | KDRCDK2KIFC1HDAC1HDAC6 | |
| SCHEMBL4829734 | 0.89 | CDK2 (0.56) | KDRCDK2KIFC1HDAC1HDAC6 | |
| SCHEMBL4824898 | 0.89 | KIFC1 (0.57) | CDK2KIFC1GPR34 | |
| SCHEMBL4824091 | 0.89 | KDR (0.60) | KDRCDK2HDAC1HDAC6TACR3 | |
| SCHEMBL4824089 | 0.89 | KDR (0.60) | KDRCDK2HDAC1HDAC6TACR3 | |
| SCHEMBL13986736 | 0.89 | KDR (0.60) | KDRCDK2HDAC1HDAC6TACR3 | |
| SCHEMBL6408089 | 0.88 | KDR (0.53) | KDRCDK2HDAC1HDAC6TACR3 | |
| SCHEMBL6408091 | 0.88 | KDR (0.53) | KDRCDK2HDAC1HDAC6TACR3 | |
| SCHEMBL4831600 | 0.87 | KDR (0.54) | KDRCDK2HDAC1HDAC6TACR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7459472-B2 | Aryl and heteroaryl compounds, compositions, and methods of use | TRANSTECH PHARMA, INC. (US) | 2008-12-02 | — | — | US | disclosed |
| US-7459472-B2 | Aryl and heteroaryl compounds, compositions, and methods of use | TRANSTECH PHARMA, INC. (US) | 2008-12-02 | — | — | US | disclosed |
| US-20050059713-A1 | Aryl and heteroaryl compounds, compositions, and methods of use | VTVX HOLDINGS I LLC | 2005-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059713-A1 | Aryl and heteroaryl compounds, compositions, and methods of use | CYP2F1, CYP3A43, PNPO | KDR 1624/4885CDK2 456/4885KIFC1 2072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.